AgingNCT05724589

The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

A study testing Epidermal Growth Factor in people with Aging, run by Institute of Dermatology, Thailand at 1 site in Thailand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

EGF is a polypeptide that promotes cell differentiation and collagen production while decreasing melanin production. This study is designed to study its effectiveness in improving the texture and appearance of facial skin after daily topical application. Read more about this study

Who is it for?: Ages 40 to 65 yearsHealthy volunteers can take part
Conditions the study is for: Aging
What is being tested?: Epidermal Growth Factor
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 28 participants
Where: 1 siteThailand
Study dates: 30 Jan 2023to 12 Dec 2024
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 65 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Thai
Mild to moderate facial skin condition, as measured by 1-2 points on the hyperpigmentation status scale or 2-3 points on the wrinkle severity grading scale.

Who cannot join

Use of lotions or skin care products containing ingredients such as vitamin A/C, hydroquinone, or anti-aging agents.
Sunbathing
Hypersensitivity to serum components
Pregnancy and breast-feeding
Active skin diseases such as eczema or atopic dermatitis at the application site

Trial locations and contacts

1 site in 1 country.

Thailand1 site

Institute of Dermatology
Bangkok, 10400

Other trials in Thailand

About this study

Official title: The Effectiveness of Epidermal Growth Factor Serum for the Improvement of Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles at the Institute of Dermatology: a Single-centered Pilot Study With a One-group Before-and-after Design

Read the detailed description

All patients gave written informed consent for epidermal growth factor serum application on the face. The pilot study enrolls thirty patients compared to pre and post-serum used to evaluate facial skin hydration, transepidermal water loss, elasticity, pigmentation, and wrinkles measured by corneometer, tewameter, cutometer, visioscan, and mexameter respectively on day 0, then 8, 12, and 16 weeks. The study evaluates subject satisfaction and side effects after serum application as secondary outcomes.

Conditions: Aging
Being tested: Epidermal Growth Factor

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Epidermal Growth FactorDrug
Also called Epidermal Growth Factor Serum
Apply facial twice daily.

Study groups in NCT05724589
Study group	Role	What they receive
Epidermal Growth Factor Serum Application	Experimental	Participants received Epidermal growth factor serum application on the face daily for two months compared to pre and post-results of skin quality. Receives: Drug: Epidermal Growth Factor

What is being measured

The primary outcome is the main question the study is designed to answer.

Facial Skin Hydration
Facial skin hydration was measured using a Corneometer, which provides readings in arbitrary units (a.u.). Measurements were taken at baseline (Day 0), Week 8, Week 12, and Week 16 under standardized environmental and procedural conditions to ensure reliability and accuracy. Higher values indicate better skin hydration, while lower values indicate increased dryness.
Measured: 4 months (Baseline, Week 8, Week 12, Week 16)
Transepidermal Water Loss
measured by tewameter on day 0, then at 8, 12, and 16 weeks.
Measured: 4 months
Facial Skin Elasticity (R2 Parameter Via Cutometer)
Skin elasticity was assessed using a Cutometer with the R2 parameter (Ua/Uf), which measures gross elasticity. R2 values range from 0 to 1.0, with higher values indicating better skin elasticity. Measurements were collected under standardized conditions at Baseline (Day 0), Week 8, Week 12, and Week 16.
Measured: Baseline, Week 8, Week 12, Week 16
Facial Skin Wrinkles
Visioscan measurements were taken at baseline, then at 8, 12, and 16 weeks by using a 4-grade percentage wrinkle improvement scale.
Measured: 4 months
Facial Melanin Index
Facial pigmentation was assessed using the Mexameter, which measures melanin content via light absorption and reflection. The device reports values on a scale from 0 to 999, where higher values represent greater melanin concentration. Measurements were collected at standardized facial sites at Baseline, Week 8, Week 12, and Week 16. Higher scores indicate worse pigmentation.
Measured: 4 months
Overall Facial Skin Appearance (Photo Evaluation Using SGAIS)
Facial skin appearance was evaluated using the Subject Global Aesthetic Improvement Scale (SGAIS), a 5-point scale where higher scores indicate greater improvement. Scores were assigned by two board-certified dermatologists who assessed photographs taken by the Visia-CR imaging system at Baseline, Week 8, Week 12, and Week 16.
SGAIS scoring definition:
1 = Worse, 2 = Mild improvement (<25%), 3 = Moderate (25-49%), 4 = Much improved (50-74%), 5 = Very much improved (≥75%).
Measured: 4 months

Secondary outcomes (2)

Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation
Using a quartile grading system, (0 = unsatisfied), (1 = slightly satisfied), (2 = satisfied), and (3 = very satisfied)
Measured: 4 months
Adverse Events
Adverse events were systematically monitored at 2, 4, 8, 12, and 16 weeks post-treatment initiation.
Measured: 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Jan 202312 Dec 2024

First posted13 Feb 2023
Study start30 Jan 2023
Primary completion5 Jun 2024
Study completion12 Dec 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for AgingStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 28 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05724589
Sponsor's protocol ID: 008/2565
Status last verified: Jul 2025
First submitted: 30 Jan 2023
Last updated: 31 Jul 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity

All Aging trials

Study at a glance

From the registry record, last updated by the sponsor on 31 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: The Effectiveness of Epidermal Growth Factor Serum for the Improvement of Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles at the Institute of Dermatology: a Single-centered Pilot Study With a One-group Before-and-after Design
ClinicalTrials.gov ID: NCT05724589
Acronym / sponsor ID: 008/2565
Conditions: Aging
Study type: Interventional
Recruitment status: Completed
Enrolment: 28 participants (actual)
Lead sponsor: Institute of Dermatology, ThailandOther government
Study start: 30 Jan 2023 (actual)
Primary completion: 5 Jun 2024 (actual)
Study completion: 12 Dec 2024 (actual)
First posted: 13 Feb 2023 (actual)
Results: Posted 31 Jul 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
Epidermal Growth Factor Serum Application	Experimental	Drug: Epidermal Growth FactorParticipants received Epidermal growth factor serum application on the face daily for two months compared to pre and post-results of skin quality.

Who may qualify

Ages: 40 to 65 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

Thai
Mild to moderate facial skin condition, as measured by 1-2 points on the hyperpigmentation status scale or 2-3 points on the wrinkle severity grading scale.

Key exclusion criteria (5 listed)

Use of lotions or skin care products containing ingredients such as vitamin A/C, hydroquinone, or anti-aging agents.
Sunbathing
Hypersensitivity to serum components
Pregnancy and breast-feeding
Active skin diseases such as eczema or atopic dermatitis at the application site

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Epidermal Growth FactorAlso: Epidermal Growth Factor SerumApply facial twice daily.	Drug	Epidermal Growth Factor Serum Application

Primary outcome

Facial Skin Hydration
Time frame: 4 months (Baseline, Week 8, Week 12, Week 16)
Facial skin hydration was measured using a Corneometer, which provides readings in arbitrary units (a.u.). Measurements were taken at baseline (Day 0), Week 8, Week 12, and Week 16 under standardized environmental and procedural conditions to ensure reliability and accuracy. Higher values indicate better skin hydration, while lower values indicate increased dryness.
Transepidermal Water Loss
Time frame: 4 months
measured by tewameter on day 0, then at 8, 12, and 16 weeks.
Facial Skin Elasticity (R2 Parameter Via Cutometer)
Time frame: Baseline, Week 8, Week 12, Week 16
Skin elasticity was assessed using a Cutometer with the R2 parameter (Ua/Uf), which measures gross elasticity. R2 values range from 0 to 1.0, with higher values indicating better skin elasticity. Measurements were collected under standardized conditions at Baseline (Day 0), Week 8, Week 12, and Week 16.
Facial Skin Wrinkles
Time frame: 4 months
Visioscan measurements were taken at baseline, then at 8, 12, and 16 weeks by using a 4-grade percentage wrinkle improvement scale.
Facial Melanin Index
Time frame: 4 months
Facial pigmentation was assessed using the Mexameter, which measures melanin content via light absorption and reflection. The device reports values on a scale from 0 to 999, where higher values represent greater melanin concentration. Measurements were collected at standardized facial sites at Baseline, Week 8, Week 12, and Week 16. Higher scores indicate worse pigmentation.
Overall Facial Skin Appearance (Photo Evaluation Using SGAIS)
Time frame: 4 months
Facial skin appearance was evaluated using the Subject Global Aesthetic Improvement Scale (SGAIS), a 5-point scale where higher scores indicate greater improvement. Scores were assigned by two board-certified dermatologists who assessed photographs taken by the Visia-CR imaging system at Baseline, Week 8, Week 12, and Week 16. SGAIS scoring definition: 1 = Worse, 2 = Mild improvement (<25%), 3 = Moderate (25-49%), 4 = Much improved (50-74%), 5 = Very much improved (≥75%).

2 secondary outcomes

Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation
Time frame: 4 months
Adverse Events
Time frame: 4 months

Results and safety

Results posted to the registry on 31 Jul 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Epidermal Growth Factor Serum Application	28	27

Primary outcome: Facial Skin Hydration

Time frame: 4 months (Baseline, Week 8, Week 12, Week 16). Mean (Standard Deviation). Unit: arbitrary units

Measure	Epidermal Growth Factor Serum Application n = 28
Baseline	56.043 (1.900)
8 weeks	58.300 (1.567)
12 weeks	55.852 (1.583)
16 weeks	58.714 (1.568)

Epidermal Growth Factor Serum Application: Mean Difference (Final Values): 2.671, p = 1.000, ANOVA

Population analysed: The analysis population included 28 subjects initially recruited for this study. Participants were assessed at four time points: baseline (Day 0), Week 8, Week 12, and Week 16. One participant was lost to follow-up after Week 12 and Week 16.

Primary outcome: Transepidermal Water Loss

Time frame: 4 months. Mean (Standard Deviation). Unit: g/m²·h

Measure	Epidermal Growth Factor Serum Application n = 28
Baseline	11.815 (1.221)
8 weeks	8.761 (0.623)
12 weeks	8.400 (0.516)
16 weeks	8.160 (0.559)

Epidermal Growth Factor Serum Application: Mean Difference (Final Values): -3.656, p = 0.096, ANOVA

Population analysed: The analysis population for this study on Transepidermal Water Loss (TEWL) utilizing Tewameter measurements comprised a total of 28 initially recruited subjects. These participants were assessed at four distinct time points: day 0 (baseline), 8 weeks, 12 weeks, and 16 weeks. One subject loss follow-up at week 12 and week 16.

Primary outcome: Facial Skin Elasticity (R2 Parameter Via Cutometer)

Time frame: Baseline, Week 8, Week 12, Week 16. Mean (Standard Deviation). Unit: units on a scale

Measure	Epidermal Growth Factor Serum Application n = 28
Baseline	0.596 (0.016)
8 wk	0.596 (0.013)
12 wk	0.584 (0.012)
16 wk	0.553 (0.014)

Epidermal Growth Factor Serum Application: Mean Difference (Final Values): -0.043, p = 0.169, ANOVA

Population analysed: 28 participants were assessed at Baseline and Week 8. One participant was lost to follow-up after Week 8, resulting in 27 participants at Weeks 12 and 16. Skin elasticity was measured using the R2 parameter from Cutometer readings at each time point.

Primary outcome: Facial Skin Wrinkles

Time frame: 4 months. Mean (Standard Deviation). Unit: units on a scale

Measure	Epidermal Growth Factor Serum Application n = 28
baseline	1 (0)
8 wk	1 (0)
12 wk	1 (0)
16 wk	1 (0)

Epidermal Growth Factor Serum Application: Mean Difference (Final Values): 1, p = 1.000, ANOVA

Population analysed: The analysis population for this study on facial skin wrinkles using Visioscan included 28 subjects, assessed at Day 0 (baseline), Week 8, Week 12, and Week 16. One subject dropped out at Week 12 and another at Week 16, leaving data from 27 participants for Weeks 12 and 16. Wrinkle improvement was assessed on a 4-grade scale: Grade 1 (0-25%) = slight, Grade 2 (25-50%) = moderate, Grade 3 (50-75%) = marked, Grade 4 (\>75%) = significant. Data are presented as mean grades with standard deviation.

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Baseline, Week 8, Week 12, Week 16. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Epidermal Growth Factor Serum Application	0 of 28 (0%)	0 of 28 (0%)	0 of 28

Limitations and caveats (from the sponsor): The small sample size should be considered. Further research involving a larger population or control group is recommended for conclusive insights into the efficacy of EGF serum.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: No

Related trials for Aging

RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Chumsaeng Chumsaengsri principal investigator

Institute of Dermatology

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Epidermal Growth Factor in people with Aging, run by Institute of Dermatology, Thailand at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Facial Skin Hydration (time frame: 4 months (Baseline, Week 8, Week 12, Week 16)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05724589.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2025.